{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-001955","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.721414+00:00","generated_at":"2026-05-16T11:13:02.220539+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Voyager Therapeutics outlines pivotal 2026 milestones: tau programs, capsid validation, NeuroShuttle data","bullets":["Biogen's BIIB080 Phase II data expected mid-2026; Voyager's VY1706 gene therapy first-in-human in H2 2026.","VY7523 anti-tau antibody trial fully enrolled; tau PET imaging data expected H2 2026.","Neurocrine plans to initiate clinical trial with NBIB-‘223 for Friedreich's ataxia in 2026.","ALPL-NeuroShuttle shows similar target engagement to TfR shuttle with more sustained brain exposure; partnering interest strong.","Four wholly owned and partnered IV-delivered neuro gene therapy programs advanced to preclinical toxicology."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-001955","json":"https://secwatch.observer/filing/0001104659-26-001955.json","markdown":"https://secwatch.observer/filing/0001104659-26-001955.md","text":"https://secwatch.observer/filing/0001104659-26-001955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926001955/0001104659-26-001955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926001955/tm262517d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:13:02.220539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}